|
SEPT2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.73509999888E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.13349999999002E-05 |
| Normal-vs-Stage2 |
3.7505999999965E-05 |
| Normal-vs-Stage3 |
6.49250000428481E-08 |
| Normal-vs-Stage4 |
1.89940000394628E-08 |
| Stage1-vs-Stage2 |
1.724380E-01 |
| Stage1-vs-Stage3 |
3.417900E-02 |
| Stage1-vs-Stage4 |
6.721300E-03 |
| Stage2-vs-Stage3 |
8.745200E-01 |
| Stage2-vs-Stage4 |
5.867600E-01 |
| Stage3-vs-Stage4 |
5.983200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.91139999944556E-07 |
| Normal-vs-AfricanAmerican |
2.203000E-03 |
| Normal-vs-Asian |
6.13360000000229E-05 |
| Caucasian-vs-AfricanAmerican |
9.738800E-01 |
| Caucasian-vs-Asian |
7.593200E-01 |
| AfricanAmerican-vs-Asian |
8.602000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.99930000011462E-07 |
| Normal-vs-Female |
3.0370000003721E-07 |
| Male-vs-Female |
6.823800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.58149999999591E-05 |
| Normal-vs-Age(41-60Yrs) |
3.10250000024048E-07 |
| Normal-vs-Age(61-80Yrs) |
4.27599999852646E-08 |
| Normal-vs-Age(81-100Yrs) |
8.453800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.182000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.212000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.289000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.474200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.343800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.871400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.371390E-01 |
| Classical-VS-Follicular |
2.445500E-04 |
| Classical-VS-Other |
2.555000E-01 |
| Classical-VS-Normal |
4.24420000000314E-05 |
| Tall-VS-Follicular |
4.186800E-01 |
| Tall-VS-Other |
7.268600E-01 |
| Tall-VS-Normal |
1.435940E-04 |
| Follicular-VS-Other |
9.276200E-01 |
| Follicular-VS-Normal |
1.44389999956474E-08 |
| Other-VS-Normal |
1.310270E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.31329999944974E-07 |
| Normal-vs-N1 |
7.58389999688802E-08 |
| N0-vs-N1 |
2.193200E-01 |
|
|
